Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- JNCI cancer spectrum
- Publicado em
- 7 jul 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis
Yu Fujiwara, Yui Okamura, Mrinalini Ramesh, Yasmin Fakhari Tehrani, Riona Aburaki, Toshiaki Takahashi, Manmeet S Ahluwalia, Sarbajit Mukherjee
Descritores MeSH
- Neoplasms
- Immune Checkpoint Inhibitors
- Humans
- Immunotherapy
- Receptors, Immunologic
- Antigens, CD
- B7-H1 Antigen
- CTLA-4 Antigen
- Programmed Cell Death 1 Receptor
- Lymphocyte Activation Gene 3 Protein
Veja também
Estudos relacionados
- Efficacy of PD-1/PD-L1 and LAG-3 immune checkpoint inhibitors in the treatment of patients with solid tumor
- Immune checkpoint inhibitor doublets: Are they beneficial for older patients? A systematic review and meta-analysis
- Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity
- Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials